SRF-miR-29b-MMP2 axis inhibits NSCLC invasion and metastasis

International Journal of Oncology

Volumn 47, Issue 2, 2015, Pages 641-649

  Wang, Hong Yan ^a   Tu, Yong Sheng ^a   Long, Jie ^a   Zhang, Hui Qiu ^a   Qi, Cui Ling ^a   Xie, Xiao Bin ^a   Li, Shu Hua ^a   Zhang, Ya Jie ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Metastasis; MiR 29b; Serum response factor

Indexed keywords

GELATINASE A; MICRORNA 29B; TRANSCRIPTION FACTOR SRF; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR; MICRORNA; MIRN29 MICRORNA, HUMAN; MMP2 PROTEIN, HUMAN; SERUM RESPONSE FACTOR; SRF PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER CELL LINE; MALE; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TUMOR INVASION; ANIMAL; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; SERUM RESPONSE FACTOR;

EID: 84932649413     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3034     Document Type: Article

References (39)

1. Shao C, Lu C, Chen L, Koty PP, Cobos E and Gao W: p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol 67: 1369-1380, 2011.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
3. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55-63, 2003.
4. Ambros V and Chen X: The regulation of genes and genomes by small RNAs. Development 134: 1635-1641, 2007.
5. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al: miR 9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010.
6. Ma L: Role of miR 10b in breast cancer metastasis. Breast Cancer Res 12: 210, 2010.
7. Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, Ma Y and Li D: Genetic heterogeneity of breast cancer metastasis may be related to miR21 regulation of TIMP-3 in translation. Int J Surg Oncol 2013: 875078, 2013.
8. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, et al: miR126 and miR126 repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 15: 284-294, 2013.
9. Liu S, Howell PM and Riker AI: Up-regulation of miR 182 expression after epigenetic modulation of human melanoma cells. Ann Surg Oncol 20: 1745-1752, 2013.
10. Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A, Kharenko O, et al: MiR 92b and miR 9/9 are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19: 375-383, 2009.
11. Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, et al: Hypermethylation of the GABRE-miR 452-miR 224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res 20: 2169-2181, 2014.
12. Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C, et al: miR 21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 12: 14, 2012.
13. Bullock MD, Pickard KM, Nielsen BS, Sayan AE, Jenei V, Mellone M, Mitter R, Primrose JN, Thomas GJ, Packham GK, et al: Pleiotropic actions of miR 21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis 4: e684, 2013.
14. Wang HY, Zheng SQ, Tu YS and Zhang YJ: Bioinformatics analysis of metastasis-related miR 29b. Chin J Clin Oncol 41: 1021-1025, 2014.
15. Hou Y, Zou Q, Ge R, Shen F and Wang Y: The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res 22: 259-272, 2012.
16. Angelastro JM and Lamé MW: Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 8: 1105-1115, 2010.
17. He A, Qi W, Huang Y, Feng T, Chen J, Sun Y, Shen Z and Yao Y: CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study. Exp Ther Med 4: 435-441, 2012.
18. Kim ST, Sohn I, Do IG, Jang J, Kim SH, Jung IH, Park JO, Park YS, Talasaz A, Lee J, et al: Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics Proteomics 11: 259-266, 2014.
19. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, Kinoshita I, Oizumi S, Dosaka-Akita H, Matsuno Y, et al: CD133 expression: A potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 19: 254-259, 2014.
20. Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW, Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene: Jun 9, 2014 (Epub ahead of print). doi: 10.1038/onc.2014.152.
21. Wang B, Li W, Liu H, Yang L, Liao Q, Cui S, Wang H and Zhao L: miR 29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition. Cell Death Dis 5: e1335, 2014.
22. Zheng JJ, Yu FJ, Dong PH, Bai YH and Chen BC: Expression of miRNA-29b and its clinical significances in primary hepatic carcinoma. Zhonghua Yi Xue Za Zhi 93: 888-891, 2013 (In Chinese).
23. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R and Wu CW: Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17: 353-360, 1997.
24. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, et al: MiR 218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6: e1000879, 2010.
25. Chang DK, Lin CT, Wu CH and Wu HC: A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One 4: e4171, 2009.
26. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW and Lin CT: Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene 27: 2137-2147, 2008.
27. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57, 2008.
28. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: e2637, 2008.
29. Q ian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y and Song Y: The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: A systematic review with metaanalysis. Cancer Invest 28: 661-669, 2010.
30. Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY and Zhuang SM: MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 54: 1729-1740, 2011.
31. Gebeshuber CA, Zatloukal K and Martinez J: miR 29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10: 400-405, 2009.
32. Kuo CH, Goldberg MD, Lin SL, Ying SY and Zhong JF: Identify intronic microRNA with bioinformatics. Methods Mol Biol 936: 77-82, 2013.
33. Beck H, Flynn K, Lindenberg KS, Schwarz H, Bradke F, Di Giovanni S and Knöll B: Serum response factor (SRF)-cofilin-actin signaling axis modulates mitochondrial dynamics. Proc Natl Acad Sci USA 109: E2523-E2532, 2012.
34. Lee HJ, Yun CH, Lim SH, Kim BC, Baik KG, Kim JM, Kim WH and Kim SJ: SRF is a nuclear repressor of Smad3-mediated TGF-beta signaling. Oncogene 26: 173-185, 2007.
35. Choi HN, Kim KR, Lee JH, Park HS, Jang KY, Chung MJ, Hwang SE, Yu HC and Moon WS: Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol Rep 21: 57-63, 2009.
36. Kim KR, Bae JS, Choi HN, Park HS, Jang KY, Chung MJ and Moon WS: The role of serum response factor in hepatocellular carcinoma: An association with matrix metalloproteinase. Oncol Rep 26: 1567-1572, 2011.
37. V erone AR, Duncan K, Godoy A, Yadav N, Bakin A, Koochekpour S, Jin JP and Heemers HV: Androgen-responsive serum response factor target genes regulate prostate cancer cell migration. Carcinogenesis 34: 1737-1746, 2013.
38. Walker T, Nolte A, Steger V, Makowiecki C, Mustafi M, Friedel G, Schlensak C and Wendel HP: Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection. Eur J Cardiothorac Surg 43: 628-634, 2013.
39. Zhao X, He L, Li T, Lu Y, Miao Y, Liang S, Guo H, Bai M, Xie H, Luo G, et al: SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR 199a-5p expression in human gastric cancer. Cell Death Differ 21: 1900-1913, 2014.